However, on the contrary, limited research suggests that epigenetic clocks, especially the ELOVL2-based epigenetic clock, may operate independently of menopause status [56], emphasizing their potential robustness and suitableness for BC clinical practice. This evidence concerns the gene ELOVL2 and breast cancer.